224 related articles for article (PubMed ID: 16990630)
1. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay S; Allison JJ; Curtis JR
Am J Health Syst Pharm; 2006 Oct; 63(19):1837-51. PubMed ID: 16990630
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
[TBL] [Abstract][Full Text] [Related]
3. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
5. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K; Fastbom J
Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
[TBL] [Abstract][Full Text] [Related]
6. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
7. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.
van Staa TP; Leufkens HG; Zhang B; Smeeth L
PLoS Med; 2009 Dec; 6(12):e1000194. PubMed ID: 19997499
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
Borer JS; Simon LS
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
10. [Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
Konishi H; Yoshikawa T
Nihon Rinsho; 2011 Jun; 69(6):1110-5. PubMed ID: 21688637
[TBL] [Abstract][Full Text] [Related]
11. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs.
García-Rayado G; Navarro M; Lanas A
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1031-1043. PubMed ID: 30139288
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study
.
Han MH; Nam JH; Noh E; Lee EK
Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273
[TBL] [Abstract][Full Text] [Related]
13. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin.
Cheetham TC; Levy G; Niu F; Bixler F
Ann Pharmacother; 2009 Nov; 43(11):1765-73. PubMed ID: 19809010
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
van den Bemt BJ; Benraad HB; Rasker JJ
Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risks of cyclooxygenase inhibition.
Stacy ZA; Dobesh PP; Trujillo TC
Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.
Scarpignato C; Hunt RH
Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of NSAIDs prescribing in Saudi Arabia: Cardiovascular and gastrointestinal risk in patients with diabetes mellitus
.
Mazhar F; Haider N; Sultana J; Akram S; Ahmed Y
Int J Clin Pharmacol Ther; 2018 Feb; 56(2):64-71. PubMed ID: 29208206
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
